View more in
Health

VBL Therapeutics Shares Drop As Pending Clearance Of New Batches Cancer Gene Therapy Hit Recruitment In Ovarian Cancer Trial

Posted by 
Benzinga
Benzinga
 2021-06-15
Cover picture for the article

The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is still ongoing. VB-111 (ofranergene obadenovec) gene therapy for ovarian cancer. Until new batches are cleared, the Company...

www.benzinga.com

Comments / 0

Comments / 0